Best Choice of ADHD Medication in an Underweight Child

Introduction to ADHD Medication

The American Academy of Child and Adolescent Psychiatry recommends atomoxetine as the best first-line medication choice for underweight children with ADHD, due to its minimal effects on weight and growth compared to stimulants 1, 2

Stimulant medications are associated with statistically significant reductions in both height and weight gain, with effects that are dose-related and clinically relevant in certain subgroups requiring careful monitoring 1
The MTA study revealed persistent effects of stimulants on decreasing growth velocity, particularly with higher and more consistently administered doses, with diminished growth in the range of 1-2 cm 3
Atomoxetine shows fewer effects on appetite and growth compared to stimulants, making it advantageous for long-term treatment in underweight children 2

Atomoxetine has demonstrated consistent efficacy in reducing ADHD core symptoms across multiple randomized, double-blind, placebo-controlled trials, with an effect size of approximately 0.7 3
Atomoxetine provides "around-the-clock" symptom coverage throughout waking hours, which benefits children who need consistent symptom control without the peaks and valleys of stimulant medications 2

The recommended starting dose for atomoxetine is 0.5 mg/kg/day for children weighing ≤70 kg or 40 mg/day for those >70 kg, with a target dose of 1.2 mg/kg/day over 7-14 days 2
Atomoxetine can be administered as a single daily dose in the morning or evening, or split into two evenly divided doses to reduce side effects 2

Regular weight monitoring is essential to objectively monitor appetite effects and weight changes in patients taking atomoxetine 4
Blood pressure and heart rate should be monitored at each dose adjustment, as atomoxetine can cause statistically significant but usually minor increases 2
Full therapeutic effect of atomoxetine requires 6-12 weeks, and patients should be closely monitored for suicidal ideation, especially during the first few months of treatment or with dose changes 2

Extended-release guanfacine or extended-release clonidine have effect sizes of approximately 0.7 and are FDA-approved for ADHD, though they may cause sedation 3, 2

Premature discontinuation of atomoxetine due to delayed onset is a frequent error, and patients should be treated for at least 6-12 weeks at target dose 2
Atomoxetine has a distinctly better profile for growth concerns compared to other ADHD medications, and behavioral interventions should be combined with medication for optimal outcomes 1, 2, 3